Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
期刊
CANCER CHEMOTHERAPY AND PHARMACOLOGY
卷 71, 期 3, 页码 581-591出版社
SPRINGER
关键词
作者
我是这篇论文的作者
推荐
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
Tanya Siddiqi, Jacob D. Soumerai, Kathleen A. Dorritie, Deborah M. Stephens, Peter A. Riedell, Jon Arnason, Thomas J. Kipps, Heidi H. Gillenwater, Lucy Gong, Lin Yang, Ken Ogasawara, Jerill Thorpe, William G. Wierda
BLOOD (2022)
How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells
Arnon Nagler, Vincenzo Maria Perriello, Lorenza Falini, Brunangelo Falini
BRITISH JOURNAL OF HAEMATOLOGY (2023)
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
Xin Jin, Meng Zhang, Rui Sun, Hairong Lyu, Xia Xiao, Xiaomei Zhang, Fan Li, Danni Xie, Xia Xiong, Jiaxi Wang, Wenyi Lu, Hongkai Zhang, Mingfeng Zhao
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung-Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Carol O'Hear, Huang Huang, Antonia Kwan, Chi-Chung Li, Emily C. Piccione, Michael C. Wei, Shen Yin, Nancy L. Bartlett
JOURNAL OF CLINICAL ONCOLOGY (2022)
Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+lymphomas
Nicholas P. Tschernia, Hillary Heiling, Allison M. Deal, Catherine Cheng, Caroline Babinec, Megan Gonzalez, J. Kaitlin Morrison, Christopher Dittus, Gianpietro Dotti, Anne W. Beaven, Jonathan S. Serody, William A. Wood, Barbara Savoldo, Natalie S. Grover
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)
Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas
Zachary Braunstein, Miguel Ruiz, Walter Hanel, Polina Shindiapina, John C. Reneau, Jonathan E. Brammer
JOURNAL OF PERSONALIZED MEDICINE (2022)
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
John F. Seymour, Thomas J. Kipps, Barbara F. Eichhorst, James D'Rozario, Carolyn J. Owen, Sarit Assouline, Nicole Lamanna, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Clemens Mellink, Brenda Chyla, Anesh Panchal, Tong Lu, Jenny Q. Wu, Yanwen Jiang, Marcus Lefebure, Michelle Boyer, Arnon P. Kater
BLOOD (2022)
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas
Ajay Major, Justin Kline, Theodore G. Karrison, Paul A. S. Fishkin, Amy S. Kimball, Adam M. Petrich, Sreenivasa Nattam, Krishna Rao, Bethany G. Sleckman, Kenneth Cohen, Koen van Besien, Aaron P. Rapoport, Sonali M. Smith
HAEMATOLOGICA (2022)
Phase I dose escalation and expansion study of golidocitinib, a highly selective JAK1 inhibitor, in relapsed or refractory peripheral T-cell lymphomas
Y. Song, D. H. Yoon, H. Yang, J. Cao, D. Ji, Y. Koh, H. Jing, H. Eom, J. Kwak, W. Lee, J. Lee, H. Shin, J. Jin, M. Wang, Z. Yang, W. S. Kim, J. Zhu
ANNALS OF ONCOLOGY (2023)
Update on CAR T-Cell Therapies for Relapsed/Refractory B-Cell Lymphomas
Stephen J. Schuster
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Oluwatobi Odetola, Shuo Ma
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2023)
How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors
Brunangelo Falini, Luca De Carolis, Enrico Tiacci
BLOOD (2022)
Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium
Yana Pikman, Sarah K. Tasian, Maria Luisa Sulis, Kristen Stevenson, Traci M. Blonquist, Beth Apsel Winger, Todd M. Cooper, Melinda Pauly, Kelly W. Maloney, Michael J. Burke, Patrick A. Brown, Nathan Gossai, Jennifer L. McNeer, Neerav N. Shukla, Peter D. Cole, Justine M. Kahn, Jing Chen, Matthew J. Barth, Jeffrey A. Magee, Lisa Gennarini, Asmani A. Adhav, Catherine M. Clinton, Nicole Ocasio-Martinez, Giacomo Gotti, Yuting Li, Shan Lin, Alma Imamovic, Cristina E. Tognon, Tasleema Patel, Haley L. Faust, Cristina F. Contreras, Anjali Cremer, Wilian A. Cortopassi, Diego Garrido Ruiz, Matthew P. Jacobson, Neekesh Dharia, Angela Su, Amanda L. Robichaud, Amy Saur Conway, Katherine Tarlock, Elliot Stieglitz, Andrew E. Place, Alexandre Puissant, Stephen P. Hunger, Annette S. Kim, Neal Lindeman, Lia Gore, Katherine A. Janeway, Lewis B. Silverman, Jeffrey W. Tyner, Marian H. Harris, Mignon L. Loh, Kimberly Stegmaier
CANCER DISCOVERY (2021)
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL
Emily C. Liang, Aya Albittar, Jennifer J. Huang, Alexandre Hirayama, Erik L. Kimble, Andrew J. Portuguese, Aude Chapuis, Mazyar Shadman, Brian G. Till, Ryan D. Cassaday, Filippo Milano, Hans -Peter Kiem, Stanley R. Riddell, Cameron J. Turtle, David G. Maloney, Jordan Gauthier
BLOOD ADVANCES (2023)
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas
Nora Liebers, Johannes Duell, Donnacha Fitzgerald, Andrea Kerkhoff, Daniel Noerenberg, Eva Kaebisch, Fabian Acker, Stephan Fuhrmann, Corinna Leng, Manfred Welslau, Jens Chemnitz, Jan-Moritz Middeke, Thomas Weber, Udo Holtick, Ralf Trappe, Roald Pfannes, Ruediger Liersch, Christian Spoer, Stefan Fuxius, Niklas Gebauer, Leandra Caille, Thomas Geer, Christian Koenecke, Ulrich Keller, Rainer Claus, Dimitrios Mougiakakos, Stephanie Mayer, Andreas Huettmann, Christiane Pott, Arne Trummer, Gerald Wulf, Uta Brunnberg, Lars Bullinger, Georg Hess, Carsten Mueller-Tidow, Bertram Glass, Georg Lenz, Peter Dreger, Sascha Dietrich
BLOOD ADVANCES (2021)
Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
E. Gonzalez-Barca, A. Boumendil, D. Blaise, M. Trneny, T. Masszi, H. Finel, M. G. Michieli, J. T. Bittenbring, G. Gritti, J. A. Snowden, M. Bishton, B. Bruno, S. Gonzalez de Villambrosia, A. Janikova, X. Leleu, A. Anagnostopoulos, X. Poire, M. Crysandt, Z. N. Ozkurt, E. Vandenberghe, M. Itala-Remes, J. Y. Cahn, E. Jantunen, W. Schroyens, J. Maertens, A. Esquirol, P. Dreger, S. Montoto, A. Sureda
BONE MARROW TRANSPLANTATION (2020)
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas
Juan-Manuel Sancho, Belen Navarro, Joan Alfons Soler Campos, Jaime Perez de Oteyza, Cristina de Barrenetxea Lekue, Marco Bregni, Silvina Grasso Cicala, Mario Spione, Cristina Mombiedro, Begona Soler, Pier Luigi Zinzani
EUROPEAN JOURNAL OF HAEMATOLOGY (2020)
Occupational Exposure to Pesticides and Chronic Lymphocytic Leukaemia in the MCC-Spain Study
Yolanda Benavente, Laura Costas, Marta Maria Rodriguez-Suarez, Juan Alguacil, Miguel Santibanez, Javier Vila, Claudia Robles, Esther Alonso, Esmeralda de la Banda, Eva Gonzalez-Barca, Trinidad Dierssen-Sotos, Eva Gimeno Vazquez, Marta Aymerich, Elias Campo, Jose J. Jimenez-Moleon, Rafael Marcos-Gragera, Gemma Castano-Vinyals, Nuria Aragones, Marina Pollan, Silvia de Sanjose, Manolis Kogevinas, Adonina Tardon, Delphine Casabonne
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2020)
Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study
Julio Garcia-Suarez, Javier de la Cruz, Angel Cedillo, Pilar Llamas, Rafael Duarte, Victor Jimenez-Yuste, Jose Angel Hernandez-Rivas, Rodrigo Gil-Manso, Mi Kwon, Pedro Sanchez-Godoy, Pilar Martinez-Barranco, Blanca Colas-Lahuerta, Pilar Herrera, Laurentino Benito-Parra, Adrian Alegre, Alberto Velasco, Arturo Matilla, Maria Concepcion Alaez-Uson, Rafael Martos-Martinez, Carmen Martinez-Chamorro, Keina Susana-Quiroz, Juan Francisco Del Campo, Adolfo de la Fuente, Regina Herraez, Adriana Pascual, Elvira Gomez, Jaime Perez-Oteyza, Elena Ruiz, Arancha Alonso, Jose Gonzalez-Medina, Lucia Nunez Martin-Buitrago, Miguel Canales, Isabel Gonzalez-Gascon, Maria Carmen Vicente-Ayuso, Susana Valenciano, Maria Garcia Roa, Pablo Estival Monteliu, Javier Lopez-Jimenez, Cristian Escolano Escobar, Javier Ortiz-Martin, Jose Luis Diez-Martin, Joaquin Martinez-Lopez
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group
Juan-Manuel Sancho, Ruben Fernandez-Alvarez, Francisco Gual-Capllonch, Esther Gonzalez-Garcia, Carlos Grande, Norma Gutierrez, Maria-Jesus Penarrubia, Ana Batlle-Lopez, Eva Gonzalez-Barca, Jose-Maria Guinea, Eva Gimeno, Francisco-Javier Penalver, Miguel Fuertes, Mariana Bastos, Jose-angel Hernandez-Rivas, Jose-Maria Moraleda, Olga Garcia, Marc Sorigue, Alejandro Martin
CANCER MEDICINE (2021)
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Bruno Paiva, Maria-Belen Vidriales, Amparo Sempere, Fabian Tarin, Enrique Colado, Celina Benavente, Maria-Teresa Cedena, Joaquin Sanchez, Teresa Caballero-Velazquez, Lourdes Cordon, Juan-Jose Garces, Catia Simoes, David Martinez-Cuadron, Teresa Bernal, Carmen Botella, Sofia Grille, Josefina Serrano, Carlos Rodriguez-Medina, Lorenzo Algarra, Juan-Manuel Alonso-Dominguez, Maria-Luz Amigo, Manuel Barrios, Raimundo Garcia-Boyero, Mercedes Colorado, Jaime Perez-Oteyza, Manuel Perez-Encinas, Lisette Costilla-Barriga, Maria-Jose Sayas, Olga Perez, Marcos Gonzalez-Diaz, Jose A. Perez-Simon, Joaquin Martinez-Lopez, Claudia Sossa, Alberto Orfao, Jesus F. San Miguel, Miguel-Angel Sanz, Pau Montesinos
LEUKEMIA (2021)
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA
Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, Yuankai Shi, Yoichi Tatsumi, Andrea Knapp, Federico Mattiello, Tina Nielsen, Deniz Sahin, Gila Sellam, Mikkel Z. Oestergaard, Umberto Vitolo, Marek Trneny
BLOOD ADVANCES (2021)
SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment
Mariana Bastos Oreiro, Reyes Martin, Pilar Gomez, Nieves Lopez Munoz, Antonia Rodriguez, Marta Liebana, Belen Navarro, Blanca Sanchez-Gonzalez, Pilar Mari, Jaime Perez de Oteiza, Antonio Gutierrez, Leyre Bento, Eva Domingo Domenech, Maria Jesus Vidal, Raquel Del Campo, Elena Perez Ceballos, Maria Infante, Alicia Roldan, Daniel Garcia Belmonte, Miriam Santero, Anna Sureda, Ramon Garcia Sanz
CANCERS (2021)
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms
David P. Steensma, Martin Wermke, Virginia M. Klimek, Peter L. Greenberg, Patricia Font, Rami S. Komrokji, Jay Yang, Andrew M. Brunner, Hetty E. Carraway, Lionel Ades, Aref Al-Kali, Juan M. Alonso-Dominguez, Ana Alfonso-Pierola, Catherine C. Coombs, H. Joachim Deeg, Ian Flinn, James M. Foran, Guillermo Garcia-Manero, Michael B. Maris, Malgorzata McMasters, Jean-Baptiste Micol, Jaime Perez De Oteyza, Felicitas Thol, Eunice S. Wang, Justin M. Watts, Justin Taylor, Richard Stone, Vikram Gourineni, Alyssa J. Marino, Huilan Yao, Benoit Destenaves, Xiaobin Yuan, Kun Yu, Sara Dar, Lernik Ohanjanian, Keisuke Kuida, Jianjun Xiao, Catherine Scholz, Antonio Gualberto, Uwe Platzbecker
LEUKEMIA (2021)
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
Julia Gonzalez-Rincon, Jose A. Garcia-Vela, Sagrario Gomez, Belen Fernandez-Cuevas, Sara Nova-Gurumeta, Nuria Perez-Sanz, Miguel Alcoceba, Marcos Gonzalez, Eduardo Anguita, Javier Lopez-Jimenez, Eva Gonzalez-Barca, Lucrecia Yanez, Ernesto Perez-Persona, Javier de la Serna, Miguel Fernandez-Zarzoso, Guillermo Deben, Francisco J. Penalver, Maria C. Fernandez, Jaime Perez de Oteyza, M. angeles Andreu, M. angeles Ruiz-Guinaldo, Raquel Paz-Arias, M. Dolores Garcia-Malo, Valle Recasens, Rosa Collado, Raul Cordoba, Belen Navarro-Matilla, Margarita Sanchez-Beato, Jose A. Garcia-Marco
PLOS ONE (2021)
A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection
R. Parody, I Sanchez-Ortega, A. Mussetti, B. Patino, M. Arnan, H. Pomares, E. Gonzalez-Barca, S. Mercadal, C. Boque, C. Maluquer, I Carro, M. Pena, V Clapes, S. Verdesoto, G. Bustamante, Ac Oliveira, C. Baca, E. Cabezudo, C. Talarn, L. Escoda, S. Ortega, N. Garcia, M. Isabel Gonzalez-Medina, Mar Sanchez-Salmeron, C. Fuste, J. Villa, E. Carreras, E. Domingo-Domenech, A. Sureda
BONE MARROW TRANSPLANTATION (2022)
Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets
Eva Gonzalez Barca, Laura Tomas-Roca, Anna Esteve, Marta Rodriguez, Lucia Gato, Ruth Alonso-Alonso, Alejandro Martin Garcia-Sancho, Raul Cordoba, Anna Monter-Rovira, Mariana Bastos-Oreiro, Juan Miguel Bergua Burgues, Maria Jose Sayas, Maria Cruz Viguria Alegria, Jose Javier Sanchez-Blanco, Monica Roig Pellicer, Hugo Daniel Luzardo Henriquez, Raquel de Ona, Maria Elena Cabezudo, Maria Stefania Infante, Jose Antonio Queizan Hernandez, Rebeca Sanz-Pamplona, Oscar Blanco, Ana Mozos, Fina Climent, Miguel Angel Piris
AMERICAN JOURNAL OF HEMATOLOGY (2023)
Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas
M. Pena, C. Montane, A. Paviglianiti, L. Hurtado, S. Gonzalez, I. Carro, C. Maluquer, E. Domingo-Domenech, E. Gonzalez-Barca, A. Sureda, A. Mussetti
BONE MARROW TRANSPLANTATION (2023)
A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia
Cristina Avendano-Sola, Antonio Ramos-Martinez, Elena Munez-Rubio, Belen Ruiz-Antoran, Rosa Malo de Molina, Ferran Torres, Ana Fernandez-Cruz, Jorge Calderon-Parra, Concepcion Payares-Herrera, Alberto Diaz de Santiago, Irene Romera-Martinez, Ilduara Pintos, Jaime Lora-Tamayo, Mikel Mancheno-Losa, Maria L. Paciello, A. L. Martinez-Gonzalez, Julia Vidan-Estevez, Maria J. Nunez-Orantos, Maria Isabel Saez-Serrano, Maria L. Porras-Leal, Maria C. Jarilla-Fernandez, Paula Villares, Jaime Perez de Oteyza, Ascension Ramos-Garrido, Lydia Blanco, Maria E. Madrigal-Sanchez, Martin Rubio-Batlles, Ana Velasco-Iglesias, Jose R. Pano-Pardo, J. A. Moreno-Chulilla, Eduardo Muniz-Diaz, Inmaculada Casas-Flecha, Mayte Perez-Olmeda, Javier Garcia-Perez, Jose Alcami, Jose L. Bueno, Rafael F. Duarte
JOURNAL OF CLINICAL INVESTIGATION (2021)
The direct and indirect effects of COVID-19 pandemic in a real-life hematological setting
Maria Condom, Alberto Mussetti, Clara Maluquer, Rocio Parody, Eva Gonzalez-Barca, Montserrat Arnan, Adaia Albasanz-Puig, Helena Pomares, Maria Queralt Salas, Itziar Carro, Marta Pena, Victoria Clapes, Cristina Baca Cano, Ana Carla Oliveira Ramos, Gabriela Sanz-Linares, Gabriel Moreno-Gonzalez, Santiago Mercadal, Concepcion Boque, Carlota Gudiol, Eva Domingo-Domenech, Anna Sureda
CANCER REPORTS (2021)